Login
Companies $YARW
$13.93 +$0.00 (0.0%) After hours
Yarrow Bioscience, Inc. logo

Yarrow Bioscience, Inc.

yarrowbioscience.com

What Do They Do?

Develops an antibody treatment for Graves’ disease and thyroid eye disease for patients with autoimmune thyroid diseases.

How Do They Make Money?

The company receives royalty payments from LEO Pharma when LEO Pharma sells Finacea foam.

FY2025 revenue

Who Are Their Customers?

The company licensed Finacea foam rights to LEO Pharma, which pays royalties when it sells the product.

Do Revenues Turn Into Profits?

No. It lost $26.5M in FY2025.

Operating income, FY2025
−5219% of revenue
▲ +32% (Loss) vs FY2024 (−$43.6M, −8710%)
Net income, FY2025
−4646% of revenue
▲ +34% (Loss) vs FY2024 (−$39.8M, −7951%)
Free cash flow, FY2025
−5811% of revenue
▲ +3% (Loss) vs FY2024 (−$34.1M, −6804%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
  • Jul 24, 2026 Completed merger with VYNE Therapeutics The combined company began trading as Yarrow Bioscience and initiated dosing in the Phase 2a/2b Graves’ disease trial.

Shrinking. Revenue fell 39% in 4 years, from $931K in FY2021 to $570K in FY2025, about 12% a year.

Pipeline focus The older report centers on a topical pan-BET inhibitor and describes an oral selective BET inhibitor in preclinical development. The later report says the topical vitiligo trial ended and shifts the oral program from psoriasis toward other immune-mediated diseases.

Who Do They Compete With?

Competes with AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, UCB, LEO Pharma, Janssen Pharmaceuticals, Roche, Eli Lilly, Pfizer, Novartis, Bausch Health, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and Ventyx Biosciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support